Reply to: “Reporting of all cardiac medications and their outcome in COVID‐19”
- 3 June 2020
- journal article
- letter
- Published by Wiley in Journal of Medical Virology
- Vol. 92 (9), 1421-1422
- https://doi.org/10.1002/jmv.25868
Abstract
No abstract availableFunding Information
- National Natural Science Foundation of China (81870417)
This publication has 9 references indexed in Scilit:
- Intelligent Image Monitoring Technology of Marine Environmental Pollution InformationJournal of Coastal Research, 2020
- Comment on "Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19"Journal of Medical Virology, 2020
- Interaction between RAAS inhibitors and ACE2 in the context of COVID-19Nature Reviews Cardiology, 2020
- Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2Cell, 2020
- Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19The New England Journal of Medicine, 2020
- Organ‐protective effect of angiotensin‐converting enzyme 2 and its effect on the prognosis of COVID‐19Journal of Medical Virology, 2020
- Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injuryScience China Life Sciences, 2020
- Ang II (Angiotensin II) Conversion to Angiotensin-(1-7) in the Circulation Is POP (Prolyloligopeptidase)-Dependent and ACE2 (Angiotensin-Converting Enzyme 2)-IndependentHypertension, 2020
- Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2Circulation, 2005